AIEgen orthopalladated hybrid polymers for efficient inactivation of the total coliforms in urban wastewater.

AIEgen orthopalladated hybrid polymers for efficient inactivation of the total coliforms in urban wastewater.

Publication date: Sep 22, 2023

Monitorable AIE polymers with a bioactive pattern are employed in advanced biomedical applications such as functional coatings, theranostic probes, and implants. After the global COVID-19 pandemic, interest in developing surfaces with superior antimicrobial, antiproliferative, and antiviral activities dramatically increased. Many formulations for biocide surfaces are based on hybrid organic/inorganic materials. Palladium (II) complexes display relevant activity against common bacteria, even higher when compared to their uncoordinated ligands. This article reports the design and synthesis of two series of orthopalladated polymers obtained by grafting a cyclopalladated fragment on two different O, N chelating Schiff base polymers. Different grafting percentages were examined and compared for each organic polymer. The fluorescence emission in the solid state was explored on organic matrixes and grafted polymers. DFT analysis provided a rationale for the role of the coordination core. The antibacterial response of the two series of hybrid polymers was tested against the total coliform group of untreated urban wastewater, revealing excellent inactivation ability.

Open Access PDF

Concepts Keywords
Antiproliferative Aiegen
Bacteria Coliforms
Base Compared
Efficient Efficient
Global Grafting


Type Source Name
disease VO efficient
disease VO inactivation
disease MESH COVID-19 pandemic
disease VO Bacteria
drug DRUGBANK Coenzyme M
disease MESH cancers
disease VO effective
disease IDO history
disease VO viable
disease IDO production
disease IDO organism
drug DRUGBANK Water
drug DRUGBANK Tropicamide
disease VO USA
disease MESH weight loss
drug DRUGBANK Nitrogen
disease VO efficiency
drug DRUGBANK Dichlorobenzene
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Ademetionine
drug DRUGBANK Trichloroethylene
disease VO time
disease IDO colony
disease VO Viruses
disease VO storage
drug DRUGBANK Aspartame
disease IDO process
disease IDO host
drug DRUGBANK Aniline
drug DRUGBANK Triethylene glycol
disease IDO pathogen
drug DRUGBANK Polyethylene glycol
drug DRUGBANK Isoxaflutole
drug DRUGBANK L-Citrulline
drug DRUGBANK Oxygen
drug DRUGBANK Trestolone
drug DRUGBANK Albendazole
drug DRUGBANK L-Valine
drug DRUGBANK Iron
disease VO Gap
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Vorinostat
drug DRUGBANK Imidacloprid
drug DRUGBANK Zinc
drug DRUGBANK Nonoxynol-9
drug DRUGBANK Benzophenone
drug DRUGBANK Guanosine
drug DRUGBANK Zinc oxide
disease MESH defects
drug DRUGBANK Activated charcoal
drug DRUGBANK Glutathione
disease MESH oxidative stress
drug DRUGBANK Guanidine
drug DRUGBANK Chloride ion
drug DRUGBANK L-Lysine
disease MESH infection
drug DRUGBANK Ethanol
pathway KEGG Biofilm formation
drug DRUGBANK Lactobacillus helveticus
drug DRUGBANK Fluorescein

Original Article

(Visited 1 times, 1 visits today)